Status:

COMPLETED

An Observational Study to Assess Change in Disease Activity and Adverse Events of Adalimumab in Chinese Pediatric Participants With Polyarticular Juvenile Idiopathic Arthritis (pJIA)

Lead Sponsor:

AbbVie

Conditions:

Polyarticular Juvenile Idiopathic Arthritis

Eligibility:

All Genders

2-17 years

Brief Summary

Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease affecting children, characterized by chronic synovitis with systemic multi-organ damage. Polyarticular juvenile idiopathic arth...

Eligibility Criteria

Inclusion

  • Male or female participants aged 2-17 years old with body weight ≥ 10kg.
  • Diagnosis of polyarticular pJIA by treating physician.
  • Adalimumab (Humira®) treatment is indicated as per Chinese label and according to judgement of the physician to Chinese clinical practice guidelines for the diagnosis and treatment of juvenile idiopathic arthritis.
  • Participants or their parents/legal guardians are able and willing to give assent as well as informed consent approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) if applicable according to local law, and to comply with the requirements of this study protocol and Adalimumab (Humira ®) label.

Exclusion

  • Participants who cannot be treated with adalimumab according to Chinese Humira® label and by judgement of treating physician.
  • Participants who receive any biological disease-modifying anti-rheumatic drugs (bDMARDs) within 6 months prior to the screening visit or who are on concomitant use of any bDMARD.
  • Post menarche adolescent female subjects who are pregnant or breastfeeding or considering becoming pregnant during the study
  • Participant is considered by the investigator or sub-investigator, for any reason, to be an unsuitable candidate for the study.

Key Trial Info

Start Date :

November 10 2022

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 8 2024

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT05411211

Start Date

November 10 2022

End Date

September 8 2024

Last Update

March 24 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

The Children's Hospital of Chongqing Medical University /ID# 232114

Chongqing, Chongqing Municipality, China, 400065

2

Wuhan Children's Hospital /ID# 242274

Wuhan, Hubei, China, 430000